Teleflex Incorporated (TFX) — Q1 2023 Form 10-Q
Business and period: Teleflex is a global medical technology company primarily selling single-use devices used in clinical and surgical procedures. This unaudited quarter ended April 2, 2023, compared with the three months ended March 27, 2022. Dollar amounts below are in millions unless noted.
Financial performance
- Revenue: $710.9, up 10.8% from $641.7. Management attributed the increase principally to $63.0 of higher sales from new products and price increases; results also benefited from five additional shipping days, while foreign exchange was a partial offset.
- Product and segment trends: OEM revenue rose 33.5% to $77.0; Americas rose 9.0% to $411.9, EMEA 4.7% to $143.3, and Asia 13.8% to $78.7. Product-category growth included Interventional (+20.7%) and OEM (+33.5%).
- Profit and margins: Gross profit was $391.4 versus $346.2, and gross margin improved to 55.1% from 54.0%, reflecting pricing, lower logistics and distribution costs, and favorable currency effects, partly offset by raw-material and labor inflation. Operating income from continuing operations was $115.0 versus $103.5. Net income was $76.7 versus $77.1; diluted EPS was $1.62 versus $1.63. SG&A increased to $232.7 from $203.9, or 32.7% of revenue versus 31.8%.
- Interest and taxes: Interest expense increased to $18.3 from $10.4; the average debt interest rate rose to 4.0% from 2.0%. The effective tax rate was 20.7% versus 17.1%, including higher expense from revaluation of certain U.S. state tax attributes.
- Cash flow: Continuing-operations operating cash flow was $84.3 versus $62.1. Capital expenditures were $21.8; investing cash outflow was $21.9. Financing cash outflow was $93.6, primarily $75.1 of debt reduction and $16.0 of dividends. Cash ended at $264.1, down from $292.0 at year-end 2022.
- Balance sheet and liquidity: Current assets were $1,428.1 and current liabilities $575.7. Current borrowings were $87.5 and long-term borrowings $1,549.5, for total borrowings of $1,637.0. Management said operating cash flow, cash on hand, and revolving-credit availability should fund operating needs, capital expenditures, and debt obligations for the next 12 months and foreseeable future. The company reported compliance with debt covenant requirements.
Changes, outlook, and risks
- Revenue growth and gross-margin improvement were accompanied by higher SG&A, R&D, and interest costs; net income was essentially flat year over year. Inventory increased to $614.1 from $578.5, and the company cited inventory purchases to maintain customer service amid supply-chain volatility.
- No specific full-year revenue or earnings guidance is stated in the supplied filing text. The 2022 restructuring plan is expected to generate annual pretax savings of $21–$23 when fully implemented. Estimated total pretax restructuring and related charges are $39–$48 for that plan and $24–$30 for the respiratory-divestiture plan; both are expected to be substantially completed in 2023.
- The second phase of the respiratory product-line divestiture to Medline was expected before the end of 2023. The filing says remaining consideration and any related gain will be recognized when realizable.
- Contingencies: The Italian medical-device payback matter has an $11.9 reserve; if enforced in its current form, estimated payments could exceed the reserve by up to $18.4. A Mexican tax/customs audit could result in import duties, fines, and surcharges that may be material; Teleflex recorded no loss contingency because a loss was not considered probable or estimable. Environmental liabilities accrued were $6.1 in total, with uncertainty that actual costs could exceed accruals. The company stated ordinary-course litigation was not expected to be material, while noting an unfavorable outcome could be adverse.
- Management highlighted risks including inflation and supply-chain disruption, labor and raw-material availability and costs, foreign exchange and interest rates, product demand and pricing, acquisition integration, restructuring execution, reimbursement changes, and general economic conditions. No significant risk-factor changes were reported for the quarter.
Investor verification points
- Assess how much of reported revenue growth reflects underlying demand, pricing, product mix, and the five extra shipping days, and whether growth persists across segments.
- Track gross-margin durability against raw-material and labor inflation, and whether higher SG&A and R&D spending yields adequate operating-profit growth.
- Monitor inventory, operating cash conversion, capital spending, and debt reduction, including the effect of higher variable-rate borrowing costs.
- Verify restructuring costs, timing, and delivery of the projected $21–$23 annual savings, as well as completion and proceeds from the Medline divestiture.
- Follow developments in the Italian payback appeals and Mexican audit, including any change to reserves or potential exposure.